Objectives. The 28-joint disease activity score (DAS-28) guides the use of biologics in RA. The aims of this study were to investigate agreement between the ESR-and CRP-based DAS-28 definitions, and to examine how this agreement may be improved.
Introduction
The 28-joint disease activity score (DAS-28) [1] for RA [2] is an important outcome for clinical practice and research, incorporating swollen joint counts (SJCs) and tender joint counts (TJCs), a self-determined assessment of patient general health and acute-phase response. Published thresholds define absolute DAS-28 scores representing remission (<2.6), mild (43.2), moderate or severe (>5.1) disease activity, and in combination with absolute score at end point, change in DAS-28 over time allows the extent of response to be categorized (none, moderate and good) [3] . While response categories and the sensitivity to change in absolute DAS-28 values are important outcomes when assessing treatment effect, in a number of European countries cross-sectional measurement of DAS-28 is crucial in determining which treatment a patient receives [4] ; for example, in the UK to qualify for anti-TNF drugs their DAS-28 must be >5.1 at two time points.
The original DAS-28 was based on ESR, but an alternative formula incorporating CRP [DAS-28(CRP)] has been developed [5] . Reasons for using CRP include not only its potential to be a more direct measure of inflammation, but also the increasing use of B-cell therapies that may have differential effects on these inflammatory markers. However, recent data from two large observational studies [6, 7] suggested that DAS-28(CRP) scores tended to be lower than DAS-28(ESR) scores and Inoue et al. [6] suggested potential new thresholds for disease activity categories for DAS-28(CRP). Subsequently, another group validated DAS-28 and EULAR response criteria based on CRP and compared them with the DAS-28 based on ESR [8] . They concluded that although DAS-28(CRP) yielded a better EULAR response more often than the DAS-28(ESR), the validation profiles (in terms of construct and criterion validity and sensitivity to change) of the two definitions were similar. The authors suggested that amending the definition may be preferable to changing thresholds for disease activity categories, and that any amendments would need to be widely applicable and based on examination of diverse data sets. These studies [6] [7] [8] obtained data from patients with established RA, and it is possible that the level of agreement between the different DAS-28 definitions might also vary with disease duration.
In the current study, we aimed to compare the different DAS definitions in an early RA cohort using regression methods as suggested by Wells et al. [8] . We also sought to investigate methods for improving agreement between definitions, especially taking into account the known age-and gender-related variations in ESR [9] . We then validated our results with data from another patient cohort with established RA.
Methods

Subjects
Data for measuring agreement and amending the DAS-28(CRP) definition were taken from the Yorkshire Early Arthritis Register (YEAR) of patients in the early stages of RA (disease duration 412 months) recruited between 1998 and the present. A comparison data set was compiled from a cohort of patients with established RA, recruited from 1999 to 2007. Patients were selected if they had both DAS(ESR) and DAS(CRP) data available at baseline. Patients whose baseline CRP was <1 were excluded because their data severely skewed the distribution of scores. Most of the early RA patients received DMARD therapy during the first 6 months of observation (SSZ 51%; MTX 47%; HCQ 1%; and none 1%). Patients in the established disease cohort received biological therapy (infliximab 53%; etanercept 34%; adalimumab 9%; anakinra 4%; and rituximab <1%), having previously failed to respond to DMARDs. One-way analysis of covariance (ANCOVA) models, including baseline values as covariates, were used to identify significant differences in HAQ improvement after 6 months among patients who according to EULAR criteria were 'good' responders, 'moderate' responders or 'non-responders'. To indicate whether age and gender affect ESR or CRP independently of other measures of disease activity, forced-entry linear regression models were constructed with either lnESR or ln(CRP + 1) as dependent variables and with age, gender, SJC-28, TJC-28 and patient assessment of disease activity visual analogue scale (VAS) included as independent variables. In order to construct a new DAS-28(CRP) definition, 0.7*lnESR [the ESR 'component' of DAS-28(ESR)] was entered as the dependent variable, with age, gender and ln(CRP + 1) included as independent variables. Regression coefficients obtained for each of the independent variables and the associated constant for the model were then added to the new DAS-28(CRP) definitions.
Results
A total of 520 early RA patients with full data for both DAS-28(ESR) and DAS-28(CRP) at baseline were included in the analysis; 284 (55%) had full data at 6 months. Eighty-six early RA patients whose CRP was <1 at baseline were excluded; median (range) ESR in these patients was 15.5 (10-100) mm/h. Three hundred and sixty-four patients with established RA were included in the baseline analysis; 189 had full data at 6 months. Baseline demographic and clinical data are summarized in Table  1 . Baseline demographic and clinical results did not differ substantively between patients who had full data available at baseline and those who did not (data not shown). Baseline DAS-28(CRP) scores were generally lower than DAS-28(ESR) scores in both the cohorts (Table 1 and Fig. 1 ).
Criterion validity
Limits of agreement. Examination of a Bland-Altman plot of the differences between DAS-28(ESR) and DAS-28 (CRP) in the early RA patients (Fig. 2) indicated that the magnitude of the differences was not related to the mean of the different DAS-28 definitions. The mean (95% CI) of the differences between the ESR-and CRP-based scores (ESR À CRP) was 0.34 (0.30, 0.38). The 95% limits of agreement (95% CI) were from À0.58 (À0.65, À0.51) to 1.26 (1.19, 1.33).
Cross-classification of DAS-28 categories. Comparing the classification of early RA patients as being in remission, or having mild, moderate or severe disease activity between DAS-28(ESR) and DAS-28(CRP), there were substantial levels of agreement when all categories were considered simultaneously (PEA = 88.5%; Tables 2 and 3 
Construct validity
Change in HAQ could be calculated for 268 patients. Mean improvements in HAQ differed significantly between EULAR responder states [DAS-28(ESR) ANCOVA F = 67.0, P < 0.001; DAS-28(CRP) F = 57.3, P < 0.001; all Bonferroni-corrected post hoc comparisons between pairs of responder states significant at P < 0.001, for either definition; Fig. 3 ] and the differences were of comparable magnitude across the different DAS-28 definitions [mean changes in HAQ were À0.86 and À0.80 for good responders; À0.46 and À0.41 for moderate responders; and 0.05 and 0.05 for non-responders, DAS-28(ESR) and DAS-28(CRP), respectively]. Non-responders showed a mean deterioration in HAQ, and in agreement with the findings of Wells et al. [8] , function improved linearly across the EULAR responder states.
Effects of age and gender on the agreement between DAS-28(ESR) and DAS-28(CRP)
Age and gender were significantly associated with both lnESR and lnCRP independently of the other DAS-28 variables in patients with early RA. In contrast to the findings of Radovits et al. [9] , there were no significant interactions between age and gender (ESR = À0.004, S.E. = 0.001, P = 0.218; CRP = 0.003, S.E. = 0.006, P = 0.565). S.E. = 0.006, P < 0.001) and lnCRP ( = 0.018, S.E. = 0.007, P = 0.013), whereas TJC-28 was not (lnESR = À0.009,
S.E. = 0.005, P = 0.071; lnCRP = À0.002, S.E. = 0.006, P = 0.695). We felt it would be important to show that adding age and gender to the DAS-28(CRP) definition would lead to improvements in agreement with DAS-28(ESR) over and above those that might be achieved simply by transforming the original DAS-28(CRP). We therefore created two new definitions, one with the same structure as the existing definition, but with modified CRP multiplier and constant, and another that also incorporated age and gender. In terms of overall PEA, both of the amended DAS-28(CRP) definitions showed better agreement with DAS-28(ESR) over the classification of patients into disease activity categories, at both time points, in patients with early or established RA ( Table 2 ). The definition that incorporated age and gender, DAS-28(CRP).2, generally performed slightly better than DAS-28(CRP).1, reducing and equalizing the amount by which DAS-28(CRP) overand underestimated DAS-28(ESR).
Agreement over 'low' disease activity was generally poor, potentially because few patients were assigned to this category in either cohort, at either time point. Agreement over the designation of 'low' disease activity was not improved by either of the two amended DAS-28(CRP) definitions. Both definitions improved agreement over EULAR response states, but to a similar degree. In terms of EULAR response, the addition of age and gender did not result in improved agreement between DAS-28(ESR) and DAS-28(CRP) beyond that which the more simple modification of DAS-28(CRP) (first new definition) achieved.
Discussion
We examined agreement between DAS-28(ESR) and DAS-28(CRP) on categories of disease activity and EULAR response states and found disagreement, particularly in low to moderate disease activity and moderate to good response. We derived new definitions using an early RA cohort and demonstrated, by application to If 'high' disease activity is important for determining access to expensive biological therapies, and DAS-28(CRP) is substituted for DAS-28(ESR) when making treatment decisions, based on the results we present here as many as 30% of the patients categorized as 'moderate' (and therefore ineligible) with CRP would be categorized 'high' using ESR. Around 30% of the patients who are considered to have shown a 'good' DAS-28(CRP) response to an experimental therapy may actually have only shown a 'moderate' DAS-28(ESR) response. In light of these concerns, it seems prudent to be cautious when considering the use of the current DAS-28(CRP) definition. It was derived from one study of repeated measurements made in 334 patients, which was not fully published [5] , but has nevertheless been adopted as a valid alternative to the DAS-28(ESR) despite mounting evidence that it produces lower scores.
Two large cohort studies from Japan [6, 7] have previously highlighted the tendency for DAS-28(CRP) to underestimate DAS-28(ESR) and recommended that changes to either the DAS-28(CRP) definition or the thresholds for disease activity and response categories should be made before DAS-28(CRP) can be considered equivalent to DAS-28(ESR). Inoue et al. [6] suggested new disease activity cut-offs of 2.3, 2.7 and 4.1. Applying these to our data from the early RA patients at 6 months, yielded exact agreement of 71.5%, which represents only a marginal improvement over the original cut-offs for DAS-28(CRP) (70.1%; Table 2 ); the gains in agreement were larger for our amended DAS-28(CRP) definitions, using the original cut-offs [DAS-28(CRP).1 74.3%; DAS-28(CRP).2 75.4%]. The cut-offs suggested by Inoue et al. [6] appear to be too low; the proportion of patients with moderate DAS-28(CRP) who had high DAS-28(ESR) was 2.7%, whereas 19.2% had low DAS-28(ESR) or were in DAS-28(ESR) remission. Matsui et al. [7] presented data for individual DAS-28 categories, from which we can determine that 488 (32.6%) of 1498 patients with moderate DAS-28(CRP) had high DAS-28(ESR), consistent with our findings. The authors also presented data from previous studies aimed at evaluating agreement between the two DAS-28 measurements, and pointed out that with the exception of the original abstract [5] , mean DAS-28(CRP) was consistently lower than mean DAS-28(ESR).
Recent works [8, 13] aimed at assessing the relationship between DAS-28(ESR) and DAS-28(CRP) reported high levels of agreement between the definitions and concluded that DAS-28(CRP) was a valid alternative to DAS-28(ESR). Wells et al. [8] calculated outcomes such as the overall PEA without reference to distribution within categories. This approach can mask differences in agreement within specific categories; over 34% of patients in their study who showed a 'good' EULAR response according to their DAS-28(CRP) results only achieved a moderate response on DAS-28(ESR). Crowson et al. [13] used the strength of correlation between DAS-28(CRP) and DAS-28(ESR) to indicate that the two could be used 'interchangeably'; however, this method may not be appropriate for assessing agreement because it does not detect consistent bias; indeed, examination of their published scatter plot suggests that in the majority of cases DAS-28(CRP) values were lower than the corresponding DAS-28(ESR). Our work highlights the need for rigorous investigation of agreement that takes into account the distribution of scores on each scale and measures category-specific agreement regarding classification into categories of status or response; overall measurements of agreement are not sufficient.
Wells et al. [8] cautioned that any transformation of the DAS-28(CRP) would need to be generalizable across different patient groups. Both of the novel definitions that we developed in this study improved agreement between the CRP-and ESR-based DAS-28 definitions, not only in the data collected at 6 months from the early RA patients whose baseline data had formed the basis for the transformations, but also at both time points in a separate cohort of patients with established disease. While we would not suggest that either of these novel definitions should be used in place of the existing DAS-28(CRP), we hope our results demonstrate that it should be possible to achieve a much better fit between DAS-28(CRP) and DAS-28(ESR) that is generalizable across different patient groups, at least for moderate to high scores. Unfortunately, our results show that agreement in the 'low' disease category was poor, even after transformation of DAS-28(CRP); Inoue et al. [6] also reported poor agreement over low DAS-28 scores. Given that ESR in patients with normal baseline CRP who were excluded from our analysis ranged up to 100 mm/h, it seems that there is quite some divergence between the two measurements of acute-phase response where there are low levels of inflammation. However, it is possible that the poor agreement is simply a function of the relatively small numbers of people in either cohort that had 'low' disease activity, either at baseline or following 6 months of therapy. Without actively selecting equal numbers of patients within each category of disease activity, this pattern is to be expected; the DAS-28 score interval representing low disease activity (2.6-3.2) only covers 6% of the 10-point scale, making it a very small category compared with those for remission (26%) and moderate (19%) or high (49%) disease activity. This fact alone may explain the relatively poor agreement observed for this category compared with others.
Although we have demonstrated that simply amending the CRP multiplier and constant in the current DAS-28(CRP) definition results in improved agreement with DAS-28(ESR), there was an additional (if comparatively small) gain to be made by including age and gender, at least in terms of classifying patients into the different cross-sectional DAS-28 categories, if not EULAR responder states. If the aim is to make DAS-28(CRP) as comparable as possible to DAS-28(ESR), it may be worth including www.rheumatology.oxfordjournals.org these extra terms in any novel DAS-28(CRP) definition. Any additional effort in terms of calculation will be negligible, or non-existent, as the use of direct electronic entry methods becomes more widespread.
There were limitations to the current study, such as the lack of complete follow-up data. Since the data came from registers of patients who were treated at a number of different centres, not enrolled in controlled clinical trials, some attrition was inevitable. However, the primary focus of the analysis was to compare the different DAS-28 definitions within each cohort; hence while the follow-up data were incomplete, the main priority was to have complete data to obtain accurate estimates of the proportions of patients in each disease activity or EULAR response category. Larger sample sizes would have increased numbers within each DAS category, allowing for greater precision in assessing agreement and deriving the novel definitions. The relatively small number of patients with low disease activity was a particular problem that was exacerbated at baseline by the exclusion of patients with CRP = 0; however, even after 6 months of DMARD therapy the proportion of patients with low disease activity was low.
It should be noted that, like the developers of DAS(CRP), we are suggesting methods for amending the existing DAS formula, rather than constructing a new tool (with attendant requirement for a more detailed assessment of construct validity). CRP is recognized as a more sensitive measure of inflammation than ESR and can be measured centrally from stored serum samples. It could be argued that if a CRP-based measure of disease activity were to entirely replace DAS-28(ESR) in the future, then the process of identifying the combination of measures that best reflects disease activity should be carried out afresh, given that their relationships with CRP could differ. The lack of agreement at lower levels of inflammation supports this possibility. Our regression analyses found a slightly stronger relationship between TJC and ESR (standardized = À0.103; P = 0.071) than CRP (standardized = À0.022; P = 0.695).
This study indicates that if comparability with DAS-28(ESR) is to be maintained, the DAS-28(CRP) definition needs adjustment, and that although further work is needed before a definition can be provided that is shown to be valid across patients of different ages, sexes, weights and levels of disease activity, and at different stages of their disease, it should be feasible to obtain one. Our data suggest that a decision needs to be made as to whether the DAS-28(CRP) definition itself should be amended, or whether new thresholds for disease activity and EULAR response categories should be determined to account for the fact that the YEAR Consortium DAS-28(CRP) values are generally lower than the DAS-28(ESR) values on which the original thresholds were based. We feel that changes should be made to the definition itself, following similar methods to those presented in this article, but using a wide range of data sets; until such a definitive revision is published, caution should be used when interpreting DAS-28(CRP) results. Non-agreement between the DAS-28(ESR) and the current DAS-28(CRP) definition may have important implications for meta-analyses, for clinicians who apply therapies based on DAS(ESR)-based clinical trials but use DAS(CRP) and for therapy driven by DAS scores.
Rheumatology key messages
. DAS-28(CRP) is often lower than DAS-28(ESR), particularly in females. . DAS-28(ESR) was 'high' in 30% of the patients with 'moderate' DAS-28(CRP). . It is possible to amend DAS-28(CRP) to improve agreement with DAS-28(ESR).
